Oveporexton: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •4 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
Oveporexton is not yet approved by any regulatory authority. All available safety data comes from clinical trials with limited participant numbers and durations (8-12 weeks in controlled trials). Long-term safety profile has not been fully established. Unexpected adverse effects may emerge with broader use.
Insomnia was reported in 43-48% of clinical trial participants, the most common adverse event. As a wake-promoting OX2R agonist, oveporexton may cause difficulty initiating or maintaining nighttime sleep, particularly if dosing timing is not optimized.
Urinary urgency (30-33%) and frequency (29-32%) were commonly reported. While generally mild and manageable, these symptoms may be bothersome and could affect quality of life.
The predecessor compound TAK-994 (danavorexton) was discontinued due to hepatotoxicity. While oveporexton has shown no liver injury signals in clinical trials to date, the class history warrants ongoing hepatic monitoring until longer-term safety data are available.
⚠️Important Warnings
- •INVESTIGATIONAL DRUG: Oveporexton (TAK-861) is not approved for any indication. It should only be used in the context of clinical trials under qualified investigator supervision.
- •Do not combine with orexin receptor antagonists (suvorexant, lemborexant), as they have pharmacologically opposing mechanisms.
- •Insomnia is common (43-48%); dosing timing should be carefully managed to minimize sleep disruption.
- •Although no hepatotoxicity has been observed with oveporexton, liver function monitoring may be warranted given the class history with TAK-994.
- •Not studied in pregnancy, lactation, or pediatric populations. Safety in these groups is unknown.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | NDA submitted to FDA and accepted with Priority Review in February 2026. PDUFA target date is Q3 2026. Not yet approved for any indication. Orphan Drug Designation granted for narcolepsy type 1. |
| European Union | Investigational | In clinical development. Regulatory submission timeline for EMA not publicly disclosed. Phase 3 trials were conducted globally including EU member states. |
| Japan | Investigational | Takeda is headquartered in Japan. Regulatory submission timeline for PMDA not publicly disclosed. Clinical development is ongoing. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
0View community protocolsCritical Safety Information#
Oveporexton (TAK-861) is an investigational drug that is not approved for any indication by any regulatory authority worldwide. The NDA has been accepted by the FDA with Priority Review, with a PDUFA target date in Q3 2026. All safety information below is derived from clinical trials and is subject to change as additional data become available.
Investigational Drug Risks#
As an unapproved investigational drug, oveporexton carries inherent uncertainties:
- Limited exposure data: Approximately 385 participants have received oveporexton in published clinical trials (Phase 2b and Phase 3), with controlled treatment durations of 8-12 weeks
- Unknown long-term effects: The safety profile beyond the trial duration has not been established. A long-term extension study is ongoing but not fully published
- Rare adverse events: Uncommon adverse effects that occur at rates of less than 1% may not have been detected given the sample sizes studied
- Population limitations: Clinical trials enrolled adults with narcolepsy type 1; safety in other populations (elderly, pediatric, hepatic/renal impairment, pregnancy) is not established
Key Identified Risks#
Insomnia#
Insomnia is the most common adverse event (43-48%), directly related to the mechanism of action. Risk mitigation includes appropriate dose timing and starting at lower doses. Most cases resolve within the first week of treatment.
Urinary Symptoms#
Urinary urgency and frequency affect approximately 30% of patients. While generally mild, these symptoms should be monitored and may require clinical management in some patients.
Class Risk: Hepatotoxicity#
TAK-994 (danavorexton), the predecessor OX2R agonist, was discontinued due to hepatotoxicity. Oveporexton has a different chemical scaffold and has shown no hepatotoxic effects in clinical trials. However, given the class history, liver function monitoring may be prudent, particularly during initial treatment.
Regulatory and Legal Status#
Oveporexton is classified as an investigational drug worldwide. It has received Orphan Drug Designation from the FDA for narcolepsy type 1.
| Jurisdiction | Status | Details |
|---|---|---|
| United States (FDA) | Investigational (NDA under Priority Review) | PDUFA Q3 2026; Orphan Drug Designation for NT1 |
| European Union (EMA) | Investigational | Phase 3 completed; regulatory filing timeline not disclosed |
| Japan (PMDA) | Investigational | Takeda headquarters; filing timeline not disclosed |
At-Risk Populations#
Pregnancy and Lactation#
Oveporexton has not been studied in pregnant or lactating women. The effects on fetal development and breast milk excretion are unknown. Women of childbearing potential participating in clinical trials were required to use effective contraception.
Pediatric Patients#
No pediatric studies have been conducted. Narcolepsy type 1 frequently presents in childhood and adolescence, so pediatric development is a recognized unmet need.
Hepatic Impairment#
While oveporexton has shown no hepatotoxicity, patients with pre-existing liver disease were likely excluded from clinical trials. Use in patients with hepatic impairment should be approached cautiously.
Patients with Insomnia Comorbidity#
Patients with narcolepsy who also have significant nighttime sleep disruption may be more susceptible to the insomnia adverse effect of oveporexton.
Risk Mitigation#
For Investigators and Future Prescribers#
- Confirm narcolepsy type 1 diagnosis before initiating treatment (CSF hypocretin-1 measurement or clinical criteria)
- Monitor for insomnia, particularly during the first week; adjust dosing timing if needed
- Monitor liver function tests, particularly given the class history with TAK-994
- Assess urinary symptoms and manage as clinically appropriate
- Review concomitant medications for pharmacological interactions (particularly orexin antagonists and CNS-active drugs)
For Patients#
- Report any new or worsening insomnia, particularly if it persists beyond the first week
- Take doses at prescribed times to optimize the balance between daytime wakefulness and nighttime sleep
- Report any signs of liver problems (yellowing of skin or eyes, dark urine, abdominal pain)
- Report urinary symptoms if they become bothersome
- Do not combine with over-the-counter sleep medications without medical guidance
Related Reading#
Frequently Asked Questions About Oveporexton
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.